<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="106050">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02117362</url>
  </required_header>
  <id_info>
    <org_study_id>14-004A</org_study_id>
    <nct_id>NCT02117362</nct_id>
  </id_info>
  <brief_title>Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma</brief_title>
  <official_title>Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Providence Health &amp; Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Providence Cancer Center, Earle A. Chiles Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Galectin Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Providence Health &amp; Services</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine a safe dose of GR-MD-02 used in combination with the
      FDA-approved dose of ipilimumab (3 mg/kg) in patients who have advanced melanoma.  GR-MD-02
      is a galectin.  Galectins are a family of proteins that have numerous functions in normal
      mammalian biology including the facilitation of cell-cell interactions, regulation of
      cell-death and regulation of immune system responses.  The hypothesis is that a safe dose of
      GR-MD-02 when given with the FDA-approved dose of ipilimumab can be found.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will employ a 3+3 phase I design with dose escalation of GR-MD-02 in conjunction
      with the standard therapeutic dose of ipilimumab in patients with advanced melanoma for whom
      ipilimumab would be considered standard of care.  In addition to monitoring for toxicity and
      clinical response, blood samples will be obtained to assess immunologic measures relevant to
      galectin biology and ipilimumab T-cell check-point inhibition
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Determine a safe dose of GR-MD-02 used in combination with the approved dose of ipilimumab (3 mg/kg)</measure>
    <time_frame>21 Days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients return to clinic 9 times in 85 days, receiving treatment on Days 1, 22, 43, and 65.  Patients will have physical exams, blood tests, and toxicity evaluations by a research nurse during this time to identify any protocol-defined dose limiting toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate to combined therapy</measure>
    <time_frame>85 Days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumor burden assessments will occur at screening, Day 85, and every 12 weeks thereafter to determine the response rate.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg/kg GR-MD-02 administered 1 hour before 3 mg/kg of ipilimumab on Days 1, 22, 43, and 65.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GR-MD-02</intervention_name>
    <description>1 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>galectin-3 inhibitor</other_name>
    <other_name>galactoarabino-rhamnogalacturonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GR-MD-02</intervention_name>
    <description>2 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>galectin-3 inhibitor</other_name>
    <other_name>galactoarabino-rhamnogalacturonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GR-MD-02</intervention_name>
    <description>4 mg/kg GR-MD-02 on Days 1, 22, 43, and 65</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>galectin-3 inhibitor</other_name>
    <other_name>galactoarabino-rhamnogalacturonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GR-MD-02</intervention_name>
    <description>8 mg/mg GR-MD-02</description>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>galectin-3 inhibitor</other_name>
    <other_name>galactoarabino-rhamnogalacturonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>3 mg/kg ipilimumab on Days 1, 22, 43, and 65</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>Yervoy</other_name>
    <other_name>Anti-CTLA 4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be ≥ 18 years of age.

          -  ECOG performance status of 0-1.

          -  Women of childbearing potential must have a serum or urine pregnancy test performed
             within 72 hours prior to the start of protocol treatment.  The results of this test
             must be negative in order for the patient to be eligible.  In addition, women of
             childbearing potential as well as male patients must agree to take appropriate
             precautions to avoid pregnancy.

          -  No active bleeding.

          -  Anticipated lifespan greater than 12 weeks.

          -  Patients must sign a study-specific consent document.

        Exclusion Criteria:

          -  Patients who have previously received a galectin antagonist

          -  Prior ipilimumab to treat metastatic melanoma (prior ipilimumab in the adjuvant
             setting is permitted if the patient did not experience ≥ grade 3 toxicity related to
             immunotherapy.

          -  Patients with active autoimmune disease except for autoimmune thyroiditis or
             vitiligo.

          -  Patients with history of colitis

          -  Patients with untreated brain metastases. Patients with treated brain metastases who
             demonstrate control of brain metastases with follow-up imaging 4 or more weeks after
             initial therapy are eligible.

          -  Other active metastatic cancer requiring treatment.

          -  Patients with active infection requiring antibiotics.

          -  Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo
             or fetus.

          -  Laboratory exclusions (to be performed within 28 days of enrollment):

          -  Need for chronic steroids.  Inhaled corticosteroids are acceptable.

          -  Inability to give informed consent and comply with the protocol. Patients with a
             history of psychiatric illness must be judged able to understand fully the
             investigational nature of the study and the risks associated with the therapy.

          -  Any medical condition that in the opinion of the Principal Investigator would
             compromise the safety or conduct of the study procedures.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brendan Curti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Health &amp; Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Fountain, RN</last_name>
    <phone>(503) 215-2691</phone>
    <email>christopher.fountain@providence.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brenda Fisher, RN</last_name>
    <phone>(503) 215-2613</phone>
    <email>brenda.fisher@providence.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brendan Curti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Crocenzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alison Conlin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Godwin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel Sanborn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Walter J. Urba, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Redmond, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keith Bahjat, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rui Li, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rom Leidner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>April 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Yervoy</keyword>
  <keyword>Galectin</keyword>
  <keyword>GR-MD-02</keyword>
  <keyword>galactoarabino-rhamnogalacturonate</keyword>
  <keyword>galectin-3 inhibitor</keyword>
  <keyword>Providence Health &amp; Services</keyword>
  <keyword>Earle A. Chiles Research Institute</keyword>
  <keyword>Robert W. Franz Cancer Center</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
